TherapeuticsMD, Inc. (TXMD)
TXMD reported positive top-line results from its Rejoice Trial designed to evaluate the safety and efficacy of three doses of the company's TX-004HR for the treatment of moderate to severe dyspareunia (vaginal pain during sexual intercourse) in postmenopausal women with vulvar and vaginal atrophy.
According to TXMD, its investigational, applicator-free vaginal estradiol softgel TX-004HR was well tolerated and demonstrated highly statistically significant results compared to placebo
TXMDshares soared over 40% in the extended session Monday, following the announcement
TXMD is an innovative healthcare company focused on developing and commercializing products exclusively for women.
Central Garden & Pet Company (CENT)
After the closing bell on Monday, CENT delivered strong profit growth in its quarterly financial results.
For its fourth quarter fiscal 2015, CENTposted sales of $1.65 billion, a 3% increase year over year, and adjusted net income of $36.6 million, or $0.74 per diluted share, compared to adjusted net income of $16.4 million, or $0.33 per diluted share in the same period the prior year.
CENTsaid that it currently expects continued growth in 2016, with adjusted earnings per fully diluted share expected to increase at least 28% to $0.95 or higher.
CENT is a leading innovator, marketer and producer of quality branded products for the lawn & garden and pet supplies markets.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer